OrgaNova TRiCBiO Publishes Landmark CRISPR Screening Study in Nature Communications

OrgaNova TRiCBiO announced the publication of a landmark study in Nature Communications demonstrating large-scale CRISPR screening in primary human 3D gastric organoids, enabling comprehensive dissection of gene-drug interactions.

The study, led by Dr. Y.H. Lo and colleagues in collaboration with Prof. Calvin Kuo's laboratory at Stanford University, establishes a new paradigm for functional genomics in clinically relevant organoid systems. The work demonstrates that genome-scale CRISPR screens can be performed directly in primary human 3D organoids—the same models used for clinical prediction—providing target validation data with unprecedented biological relevance.

"This work represents the convergence of our two core capabilities: organoid biology and functional genomics," said Wei He, PhD, Co-Founder and CSO. "It opens a new chapter in how the industry will approach target discovery and drug-gene interaction studies."

The publication is freely available in Nature Communications.